Adlarity: A Second Cholinesterase Inhibitor Patch Is Approved
The Carlat Geriatric Psychiatry Report, Volume 1, Number 1&2, January 2022
On March 14, 2022, Adlarity (donepezil hydrochloride) received FDA approval for the treatment of patients with mild, moderate, or severe Alzheimer’s dementia. Adlarity is as effective as other cholinesterase inhibitors.
You can't view details of this content, please login or buy subscription here